2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data

Background

Although the psychological burden of patients with malignant diseases is marked as one of the main aspects in the disease trajectory, anxiety and depression are still unmet need in practice. To determine influence of Anxiety and Depression on survival in patients with diagnosed lung cancer (LC) after 7 years survival follow up (SFU) period.

Methods

During the period January 2014 to May 2015 patients with LC were rated themselves on Hospital Anxiety Depression Scale (HADS). Subjects with history of psychiatric disorders and/or undergone curative surgical procedure were excluded from the study. Last SFU was done on February 28th 2023.

Results

Out of 298 screened patients 206 were included in SFU. Majority of included subjects were male 156 (75.7%), ECOPG PS 1 153 (74.3%), smokers 120 (58.3%) in Stage III 88 (42.7%) and IV 85 (41.3%) with diagnosed lung adenocarcinoma 95 (46.1%) followed by sqamouse cell LC 79 (38.3%) and SCLC 28 (13.6%). Psychiatric disorder was verified in 81 (39.3%) subjects. Out of those depression was found in 35 (43.2%) anxiety in 7 (8.6%) and combined anxiety and depression in 39 (48.2%) subjects. One-year survival was 66,5%, 3-year 26,2%, 5- year 14.1% and 7-year 8.7%. Difference in survival rate was observed between subjects with and without disorders in 1-, 3-, 5- and 7-years survival rate (61.7% vs. 69.6%; 19.8% vs. 30.4%; 11.1% vs. 16.0% and 4.9% vs. 11.2% respectively). Statistically significant difference was found in survival time between subjects with and without psychiatric disorders (25.9 vs. 49.5 Months; p=0.046). The lowest survival time was observed in group with combined anxiety and depression (21.2 Months) followed by only depression or anxiety (30.3 Months) in comparison with subjects without disorders (49.5 Months) (p=0.033).

Conclusions

Based on the results of this research, psychiatric disorders are highly prevalent and also affect the survival time of patients with LC. Despite the evidences psychological aspect is still neglected in patients with diagnosed malignancies. Easy-to-use tools for determination of anxiety and depression such as HADS should be applied regularly in clinical practice in order to recognize those disorders and to introduce adequate treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Institute for Pulmonary Diseases of Vojvodina, Serbia.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.